Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| AGIOS PHARMACEUTICALS, INC.AGIO · Entity 4499 | Director | June 18, 2026 | June 23, 2026 |
| ALPINE IMMUNE SCIENCES, INC.NVLS · Entity 90802 | Director | November 01, 2016 | November 04, 2016 |
| Akebia Therapeutics, Inc.AKBA · Entity 6105 | Director | June 17, 2026 | June 22, 2026 |
| Protara Therapeutics, Inc.TARA · Entity 6203 | Director | June 15, 2026 | June 16, 2026 |
| Spero Therapeutics, Inc.SPRO · Entity 7014 | Director | June 23, 2026 | June 25, 2026 |
| Tvardi Therapeutics, Inc.TVRD · Entity 7579 | Director | June 09, 2026 | June 11, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
AGIOS PHARMACEUTICALS, INC.
Report date June 18, 2026 · Filed June 23, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common stockSEC Table I · non-derivative | Direct | 15,230 |
Reported balance
After 2026-06-18 transaction · row 1
1 source rowRow 1 · 2026-06-18 · Exercise / conversion · Acquired 2,816 · Balance 15,230 |
| Restricted stock unitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2026-06-18 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-06-18 · Exercise / conversion · Disposed 2,816 · Balance 0 F1: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. F2: The restricted stock units were granted on June 18, 2025. The shares underlying the stock units will vest in full on June 18, 2026. Vested shares will be delivered to the reporting person within three business days after such shares become vested. |
| Restricted stock unitsSEC Table II · derivative / convertible security | Direct | 2,927 |
Reported balance
After 2026-06-18 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-06-18 · Grant · Acquired 2,927 · Balance 2,927 F1: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. F3: The restricted stock units were granted on June 18, 2026. The shares underlying the stock units will vest in full on June 18, 2027. Vested shares will be delivered to the reporting person within three business days after such shares become vested. |
| Stock options (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $34.16 · Expires 2036-06-18 | Direct | 14,950 |
Reported balance
After 2026-06-18 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-06-18 · Grant · Acquired 14,950 · Balance 14,950 F4: These options were granted on June 18, 2026. The shares underlying these options vest as to 100% of the underlying shares on June 18, 2027. |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock.
F2: The restricted stock units were granted on June 18, 2025. The shares underlying the stock units will vest in full on June 18, 2026. Vested shares will be delivered to the reporting person within three business days after such shares become vested.
F3: The restricted stock units were granted on June 18, 2026. The shares underlying the stock units will vest in full on June 18, 2027. Vested shares will be delivered to the reporting person within three business days after such shares become vested.
F4: These options were granted on June 18, 2026. The shares underlying these options vest as to 100% of the underlying shares on June 18, 2027.
ALPINE IMMUNE SCIENCES, INC.
Report date November 01, 2016 · Filed November 04, 2016
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.88 · Expires 2026-11-01 | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2016-11-01 · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · Balance Not disclosed F2: The exercise price is equal to the closing price per share of Common Stock as reported on the Nasdaq Global Market on the date of grant of November 1, 2016. F1: The shares shall vest in 36 equal monthly installments commencing on November 1, 2016. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares shall vest in 36 equal monthly installments commencing on November 1, 2016.
F2: The exercise price is equal to the closing price per share of Common Stock as reported on the Nasdaq Global Market on the date of grant of November 1, 2016.
Akebia Therapeutics, Inc.
Report date June 17, 2026 · Filed June 22, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 196,633 |
Reported balance
After 2026-06-17 transaction · row 1
1 source rowRow 1 · 2026-06-17 · Grant · Acquired 35,700 · Balance 196,633 F1: The restricted stock units (the "RSUs") were granted by the Issuer pursuant to its 2023 Stock Incentive Plan (the "2023 Plan"), as provided by the Issuer's Fifth Amended and Restated Non-Employee Director Compensation Program (the "Program"). The RSUs will vest in full (100%) on the first anniversary of the grant date (or, if earlier, immediately prior to the first annual meeting of the Company's stockholders occurring after the date of grant), subject to the Reporting Person's continuous service to the Issuer through such vesting date. |
| Stock Option (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.02 · Expires 2036-06-17 | Direct | 53,600 |
Reported balance
After 2026-06-17 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-06-17 · Grant · Acquired 53,600 · Balance 53,600 F2: The option to purchase shares of the Issuer's common stock (the "Stock Option") was granted by the Issuer pursuant to the 2023 Plan, as provided by the Program. The Stock Option will vest and become exercisable in full (100%) on the first anniversary of the grant date (or, if earlier, immediately prior to the first annual meeting of the Company's stockholders occurring after the date of grant), subject to the Reporting Person's continuous service to the Issuer through such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The restricted stock units (the "RSUs") were granted by the Issuer pursuant to its 2023 Stock Incentive Plan (the "2023 Plan"), as provided by the Issuer's Fifth Amended and Restated Non-Employee Director Compensation Program (the "Program"). The RSUs will vest in full (100%) on the first anniversary of the grant date (or, if earlier, immediately prior to the first annual meeting of the Company's stockholders occurring after the date of grant), subject to the Reporting Person's continuous service to the Issuer through such vesting date.
F2: The option to purchase shares of the Issuer's common stock (the "Stock Option") was granted by the Issuer pursuant to the 2023 Plan, as provided by the Program. The Stock Option will vest and become exercisable in full (100%) on the first anniversary of the grant date (or, if earlier, immediately prior to the first annual meeting of the Company's stockholders occurring after the date of grant), subject to the Reporting Person's continuous service to the Issuer through such vesting date.
Protara Therapeutics, Inc.
Report date June 15, 2026 · Filed June 16, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.94 · Expires 2036-06-14 | Direct | 31,000 |
Reported balance
After 2026-06-15 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-15 · Grant · Acquired 31,000 · Balance 31,000 F1: 1. The shares subject to the Annual Grant will vest in full upon the first anniversary of the date of grant, subject to the Eligible Director's continuous service as a member of the Board through such vesting date and will vest in full upon a Change of Control. |
Filing footnotes · ownership attribution and instrument terms
F1: 1. The shares subject to the Annual Grant will vest in full upon the first anniversary of the date of grant, subject to the Eligible Director's continuous service as a member of the Board through such vesting date and will vest in full upon a Change of Control.
Spero Therapeutics, Inc.
Report date June 23, 2026 · Filed June 25, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 85,000 |
Reported balance
After 2026-06-23 transaction · row 1
1 source rowRow 1 · 2026-06-23 · Grant · Acquired 10,000 · Balance 85,000 F1: Consists of restricted stock units ("RSUs"). Each RSU represents the right to receive one share of common stock upon vesting. The RSUs vest on June 23, 2027, subject to the Reporting Person's continued service through the applicable vesting date. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.15 · Expires 2036-06-23 | Direct | 20,000 |
Reported balance
After 2026-06-23 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-06-23 · Grant · Acquired 20,000 · Balance 20,000 F2: The shares underlying this option will vest and become exercisable in full on June 23, 2027 subject to the Reporting Person's continued service as a director through the vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Consists of restricted stock units ("RSUs"). Each RSU represents the right to receive one share of common stock upon vesting. The RSUs vest on June 23, 2027, subject to the Reporting Person's continued service through the applicable vesting date.
F2: The shares underlying this option will vest and become exercisable in full on June 23, 2027 subject to the Reporting Person's continued service as a director through the vesting date.
Tvardi Therapeutics, Inc.
Report date June 09, 2026 · Filed June 11, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.78 · Expires 2036-06-08 | Direct | 6,000 |
Reported balance
After 2026-06-09 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-09 · Grant · Acquired 6,000 · Balance 6,000 F1: 100% of the shares underlying the option shall vest on the earlier of June 9, 2027 or the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continuous service through such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: 100% of the shares underlying the option shall vest on the earlier of June 9, 2027 or the date of the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continuous service through such vesting date.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Dicerna Pharmaceuticals Inc
Report date December 28, 2021 · Filed December 29, 2021
Section 16 reporting ended · disclosed 2021-12-29. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2021-12-28 transaction · row 1
1 source rowRow 1 · 2021-12-28 · Other · Disposed 3,333 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of November 17, 2021, by and among the Issuer, Novo Nordisk A/S, a Danish aktieselskab ("Novo"), and NNUS New Research, Inc., a Delaware corporation and a wholly owned indirect subsidiary of Novo ("Purchaser"), to which Purchaser completed a tender offer for shares of common stock of Issuer, $0.0001 par value per share (each, a "Share") and thereafter merged with and into the Issuer (the "Merger") effective as of December 28, 2021 (the "Effective Time"). At the Effective Time, each issued and outstanding Share was converted into the right to receive $38.25 per Share, in cash, without interest (the "Offer Price") and subject to any withholding of taxes, upon the terms and subject to the conditions of the Merger Agreement. From and after the Effective Time, all Shares were no longer outstanding and were automatically cancelled. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2021-12-28 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2021-12-28 · Disposition to issuer · Disposed 3,333 · Balance 0 F2: Each restricted stock unit ("RSU") represents the contingent right to receive one Share. F3: At the Effective Time, each Issuer RSU that was then outstanding was cancelled and converted into the right to receive a cash payment equal to (A) the Offer Price multiplied by (B) the total number of Shares subject to such Issuer RSU immediately prior to the Effective Time (without regard to vesting). |
| Director Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $14.76 | Direct | 0 |
Reported balance
After 2021-12-28 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2021-12-28 · Disposition to issuer · Disposed 25,000 · Balance 0 F4: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, an "Issuer Stock Option") that was outstanding and unexercised was cancelled and converted into the right to receive a cash payment equal to (A) the excess, if any, of (x) the Offer Price over (y) the exercise price payable per Share with respect to such Issuer Stock Option, multiplied by (B) the total number of Shares subject to such Issuer Stock Option immediately prior to the Effective Time (without regard to vesting). |
| Director Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $15.44 | Direct | 0 |
Reported balance
After 2021-12-28 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2021-12-28 · Disposition to issuer · Disposed 25,000 · Balance 0 F4: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, an "Issuer Stock Option") that was outstanding and unexercised was cancelled and converted into the right to receive a cash payment equal to (A) the excess, if any, of (x) the Offer Price over (y) the exercise price payable per Share with respect to such Issuer Stock Option, multiplied by (B) the total number of Shares subject to such Issuer Stock Option immediately prior to the Effective Time (without regard to vesting). |
| Director Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $21.61 | Direct | 0 |
Reported balance
After 2021-12-28 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2021-12-28 · Disposition to issuer · Disposed 15,000 · Balance 0 F4: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, an "Issuer Stock Option") that was outstanding and unexercised was cancelled and converted into the right to receive a cash payment equal to (A) the excess, if any, of (x) the Offer Price over (y) the exercise price payable per Share with respect to such Issuer Stock Option, multiplied by (B) the total number of Shares subject to such Issuer Stock Option immediately prior to the Effective Time (without regard to vesting). |
| Director Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $30.47 | Direct | 0 |
Reported balance
After 2021-12-28 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2021-12-28 · Disposition to issuer · Disposed 15,000 · Balance 0 F4: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, an "Issuer Stock Option") that was outstanding and unexercised was cancelled and converted into the right to receive a cash payment equal to (A) the excess, if any, of (x) the Offer Price over (y) the exercise price payable per Share with respect to such Issuer Stock Option, multiplied by (B) the total number of Shares subject to such Issuer Stock Option immediately prior to the Effective Time (without regard to vesting). |
Filing footnotes · ownership attribution and instrument terms
F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of November 17, 2021, by and among the Issuer, Novo Nordisk A/S, a Danish aktieselskab ("Novo"), and NNUS New Research, Inc., a Delaware corporation and a wholly owned indirect subsidiary of Novo ("Purchaser"), to which Purchaser completed a tender offer for shares of common stock of Issuer, $0.0001 par value per share (each, a "Share") and thereafter merged with and into the Issuer (the "Merger") effective as of December 28, 2021 (the "Effective Time"). At the Effective Time, each issued and outstanding Share was converted into the right to receive $38.25 per Share, in cash, without interest (the "Offer Price") and subject to any withholding of taxes, upon the terms and subject to the conditions of the Merger Agreement. From and after the Effective Time, all Shares were no longer outstanding and were automatically cancelled.
F2: Each restricted stock unit ("RSU") represents the contingent right to receive one Share.
F3: At the Effective Time, each Issuer RSU that was then outstanding was cancelled and converted into the right to receive a cash payment equal to (A) the Offer Price multiplied by (B) the total number of Shares subject to such Issuer RSU immediately prior to the Effective Time (without regard to vesting).
F4: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, an "Issuer Stock Option") that was outstanding and unexercised was cancelled and converted into the right to receive a cash payment equal to (A) the excess, if any, of (x) the Offer Price over (y) the exercise price payable per Share with respect to such Issuer Stock Option, multiplied by (B) the total number of Shares subject to such Issuer Stock Option immediately prior to the Effective Time (without regard to vesting).
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 28, 2021 Filed Dec 29, 2021 16:21 UTC | Dicerna Pharmaceuticals Inc DRNA · Entity 131951 | OtherCommon Stock | 3,333 | $38.25 | $127,487.25 |
DisclosureSEC source: 0001399529-21-000204 · wf-form4_164081289891815.xml · nonDerivative · entry 1 Smith Cynthia · CIK 0001609480 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of November 17, 2021, by and among the Issuer, Novo Nordisk A/S, a Danish aktieselskab ("Novo"), and NNUS New Research, Inc., a Delaware corporation and a wholly owned indirect subsidiary of Novo ("Purchaser"), to which Purchaser completed a tender offer for shares of common stock of Issuer, $0.0001 par value per share (each, a "Share") and thereafter merged with and into the Issuer (the "Merger") effective as of December 28, 2021 (the "Effective Time"). At the Effective Time, each issued and outstanding Share was converted into the right to receive $38.25 per Share, in cash, without interest (the "Offer Price") and subject to any withholding of taxes, upon the terms and subject to the conditions of the Merger Agreement. From and after the Effective Time, all Shares were no longer outstanding and were automatically cancelled. F1 · shares: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of November 17, 2021, by and among the Issuer, Novo Nordisk A/S, a Danish aktieselskab ("Novo"), and NNUS New Research, Inc., a Delaware corporation and a wholly owned indirect subsidiary of Novo ("Purchaser"), to which Purchaser completed a tender offer for shares of common stock of Issuer, $0.0001 par value per share (each, a "Share") and thereafter merged with and into the Issuer (the "Merger") effective as of December 28, 2021 (the "Effective Time"). At the Effective Time, each issued and outstanding Share was converted into the right to receive $38.25 per Share, in cash, without interest (the "Offer Price") and subject to any withholding of taxes, upon the terms and subject to the conditions of the Merger Agreement. From and after the Effective Time, all Shares were no longer outstanding and were automatically cancelled. F1 · price: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of November 17, 2021, by and among the Issuer, Novo Nordisk A/S, a Danish aktieselskab ("Novo"), and NNUS New Research, Inc., a Delaware corporation and a wholly owned indirect subsidiary of Novo ("Purchaser"), to which Purchaser completed a tender offer for shares of common stock of Issuer, $0.0001 par value per share (each, a "Share") and thereafter merged with and into the Issuer (the "Merger") effective as of December 28, 2021 (the "Effective Time"). At the Effective Time, each issued and outstanding Share was converted into the right to receive $38.25 per Share, in cash, without interest (the "Offer Price") and subject to any withholding of taxes, upon the terms and subject to the conditions of the Merger Agreement. From and after the Effective Time, all Shares were no longer outstanding and were automatically cancelled. Read SEC document |
| August 17, 2021 Filed Aug 18, 2021 21:06 UTC | Spero Therapeutics, Inc. SPRO · Entity 7014 | GrantStock Option (right to buy) · Derivative | 7,500 | $0.00 Strike: $13.69 | $0.00 |
DisclosureSEC source: 0000899243-21-033477 · doc4.xml · derivative · entry 1 Smith Cynthia · CIK 0001609480 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,500 Underlying: Common Stock · 7,500 shares Expires 2031-08-27 F1 · derivative.exercise_date: The shares underlying this option will vest and become exercisable in full on August 17, 2022 subject to the Reporting Person's continued service as a director through the vesting date. Read SEC document |
| June 09, 2021 Filed Jun 11, 2021 00:11 UTC | Protara Therapeutics, Inc. TARA · Entity 6203 | GrantStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $10.51 | $0.00 |
DisclosureSEC source: 0001209191-21-039688 · doc4.xml · derivative · entry 1 Smith Cynthia · CIK 0001609480 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2031-06-08 F1 · derivative.exercise_date: The shares will vest in equal monthly installments over the 12 months following the date of grant, provided that the shares will, in any case, be fully vested on the date of the Company's next annual stockholder meeting, subject to the optionholder's continuous service as a member of the Board through such vesting date and will vest in full upon a Change of Control. Read SEC document |
| June 03, 2021 Filed Jun 7, 2021 21:35 UTC | Dicerna Pharmaceuticals Inc DRNA · Entity 131951 | GrantDirector Stock Option (Right to Buy) · Derivative | 15,000 | $0.00 Strike: $30.47 | $0.00 |
DisclosureSEC source: 0001399529-21-000110 · wf-form4_162311611046784.xml · derivative · entry 4 Smith Cynthia · CIK 0001609480 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2031-06-02 F4 · derivative.exercise_date: This option vests monthly over 12 months from the Grant Date in substantially equal monthly installments, provided that the option will vest in full on the next regularly scheduled annual meeting of the stockholders of the Issuer that occurs following the Grant Date, subject to the Reporting Person's continued service to the Issuer as a director through each such date or, if earlier, such annual meeting. Read SEC document |
| June 03, 2021 Filed Jun 7, 2021 21:35 UTC | Dicerna Pharmaceuticals Inc DRNA · Entity 131951 | GrantRestricted Stock Units · Derivative | 3,333 | $0.00 | $0.00 |
DisclosureSEC source: 0001399529-21-000110 · wf-form4_162311611046784.xml · derivative · entry 3 Smith Cynthia · CIK 0001609480 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,333 Underlying: Common Stock · 3,333 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents the contingent right to receive one share of the Issuer's Common Stock. F3 · derivative.exercise_date: Represents RSUs that shall vest and become nonforfeitable with respect to one-hundred percent (100%) of the total number of RSUs on the earlier of (i) 12 months from June 3, 2021 ("Grant Date") and (ii) the next regularly scheduled annual meeting of stockholders of the Issuer that occurs following the Grant Date, subject to the Reporting Person's continued service to the Issuer as a director through such date or, if earlier, such annual meeting. F3 · derivative.expiration_date: Represents RSUs that shall vest and become nonforfeitable with respect to one-hundred percent (100%) of the total number of RSUs on the earlier of (i) 12 months from June 3, 2021 ("Grant Date") and (ii) the next regularly scheduled annual meeting of stockholders of the Issuer that occurs following the Grant Date, subject to the Reporting Person's continued service to the Issuer as a director through such date or, if earlier, such annual meeting. Read SEC document |
| June 03, 2021 Filed Jun 7, 2021 21:35 UTC | Dicerna Pharmaceuticals Inc DRNA · Entity 131951 | Exercise / conversionRestricted Stock Units · Derivative | 3,333 | $0.00 | $0.00 |
DisclosureSEC source: 0001399529-21-000110 · wf-form4_162311611046784.xml · derivative · entry 2 Smith Cynthia · CIK 0001609480 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,333 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents the contingent right to receive one share of the Issuer's Common Stock. F2 · derivative.exercise_date: Represents RSUs that vested and became nonforfeitable with respect to one-hundred percent (100%) of the total number of RSUs on June 3, 2021. F2 · derivative.expiration_date: Represents RSUs that vested and became nonforfeitable with respect to one-hundred percent (100%) of the total number of RSUs on June 3, 2021. Read SEC document |
| June 03, 2021 Filed Jun 7, 2021 21:35 UTC | Dicerna Pharmaceuticals Inc DRNA · Entity 131951 | Exercise / conversionCommon Stock | 3,333 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001399529-21-000110 · wf-form4_162311611046784.xml · nonDerivative · entry 1 Smith Cynthia · CIK 0001609480 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,333 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit ("RSU") represents the contingent right to receive one share of the Issuer's Common Stock. Read SEC document |
| June 02, 2021 Filed Jun 3, 2021 21:27 UTC | Akebia Therapeutics, Inc. AKBA · Entity 6105 | GrantStock Option (Right to buy) · Derivative | 20,100 | $0.00 Strike: $3.37 | $0.00 |
DisclosureSEC source: 0001562180-21-004030 · primarydocument.xml · derivative · entry 2 Smith Cynthia · CIK 0001609480 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,100 Underlying: Common Stock · 20,100 shares Expires 2031-06-02 F2 · shares: The option to purchase shares of the Issuer's common stock (the "Stock Option") was granted by the Issuer pursuant to the 2014 Plan, as provided by the Program. The Stock Option will vest and become exercisable in full (100%) on the first anniversary of the grant date, subject to the Reporting Person's continued service to the Issuer. Read SEC document |
| June 02, 2021 Filed Jun 3, 2021 21:27 UTC | Akebia Therapeutics, Inc. AKBA · Entity 6105 | GrantCommon Stock | 13,700 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-21-004030 · primarydocument.xml · nonDerivative · entry 1 Smith Cynthia · CIK 0001609480 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,533 F1 · shares: The restricted stock units (the "RSUs") were granted by the Issuer pursuant to its 2014 Incentive Plan, as amended (the "2014 Plan"), as provided by the Issuer's Amended and Restated Non-Employee Director Compensation Program (the "Program"). The RSUs will vest in full (100%) on the first anniversary of the grant date, subject to the Reporting Person's continued service to the Issuer. Read SEC document |
| January 29, 2021 Filed Feb 2, 2021 00:09 UTC | Protara Therapeutics, Inc. TARA · Entity 6203 | GrantStock Option (Right to Buy) · Derivative | 3,750 | $0.00 Strike: $17.98 | $0.00 |
DisclosureSEC source: 0001209191-21-006571 · doc4.xml · derivative · entry 2 Smith Cynthia · CIK 0001609480 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,750 Underlying: Common Stock · 3,750 shares Expires 2031-01-28 F2 · derivative.exercise_date: The shares will vest in equal monthly installments over the 12 months following the date of grant, provided that the shares will, in any case, be fully vested on the date of the Company's next annual stockholder meeting, subject to the optionholder's continuous service as a member of the Board through such vesting date and will vest in full upon a Change of Control. Read SEC document |
| January 29, 2021 Filed Feb 2, 2021 00:09 UTC | Protara Therapeutics, Inc. TARA · Entity 6203 | GrantStock Option (Right to Buy) · Derivative | 18,000 | $0.00 Strike: $17.98 | $0.00 |
DisclosureSEC source: 0001209191-21-006571 · doc4.xml · derivative · entry 1 Smith Cynthia · CIK 0001609480 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,000 Underlying: Common Stock · 18,000 shares Expires 2031-01-28 F1 · derivative.exercise_date: The shares vest in a series of 36 successive equal monthly installments over the three-year period measured from the date of grant, subject to the optionholder's continuous service as a member of the Board through such vesting date and will vest in full upon a Change of Control. Read SEC document |
| January 04, 2021 Filed Jan 6, 2021 21:28 UTC | Spero Therapeutics, Inc. SPRO · Entity 7014 | GrantStock Option (right to buy) · Derivative | 2,629 | $13.31 Strike: $17.93 | $34,991.99 |
DisclosureSEC source: 0000899243-21-000692 · doc4.xml · derivative · entry 1 Smith Cynthia · CIK 0001609480 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,629 Underlying: Common Stock · 2,629 shares Expires 2031-01-04 F2 · price: This stock option was issued to the Reporting Person, who elected to take stock options in lieu of $35,000 in cash compensation for services as a director, pursuant to the Issuer's non-employee director compensation policy. F1 · derivative.exercise_date: This stock option shall vest in four quarterly installments on the last day of each calendar quarter during the calendar year subject to the Reporting Person's continued service as a non-employee director. Read SEC document |
| October 27, 2020 Filed Oct 27, 2020 21:35 UTC | Spero Therapeutics, Inc. SPRO · Entity 7014 | GrantStock Option (right to buy) · Derivative | 7,500 | $0.00 Strike: $13.52 | $0.00 |
DisclosureSEC source: 0000899243-20-029334 · doc4.xml · derivative · entry 1 Smith Cynthia · CIK 0001609480 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,500 Underlying: Common Stock · 7,500 shares Expires 2030-10-27 F1 · derivative.exercise_date: The shares underlying this option will vest and become exercisable in full on October 27, 2021 subject to the Reporting Person's continued service as a director through the vesting date. Read SEC document |
| June 15, 2020 Filed Jun 16, 2020 20:05 UTC | Dicerna Pharmaceuticals Inc DRNA · Entity 131951 | GrantDirector Stock Option (Right to Buy) · Derivative | 15,000 | $0.00 Strike: $21.61 | $0.00 |
DisclosureSEC source: 0000899243-20-016733 · doc4.xml · derivative · entry 2 Smith Cynthia · CIK 0001609480 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2030-06-14 F2 · derivative.exercise_date: This option vests monthly over 12 months from the Grant Date in substantially equal monthly installments, provided that the option vests in full on the Issuer's next regularly scheduled annual meeting of stockholders that occurs following the Grant Date, subject to the Reporting Person's continued service to the Issuer through each applicable vesting date or, if earlier, such annual meeting. Read SEC document |
| June 15, 2020 Filed Jun 16, 2020 20:05 UTC | Dicerna Pharmaceuticals Inc DRNA · Entity 131951 | GrantRestricted Stock Units · Derivative | 3,333 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-20-016733 · doc4.xml · derivative · entry 1 Smith Cynthia · CIK 0001609480 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,333 Underlying: Common Stock · 3,333 shares Expires not disclosed F1 · derivative.exercise_price: Represents restricted stock units ("RSUs") that vest 12 months from June 15, 2020 ("Grant Date"), provided that these RSUs vest in full on the Issuer's next regularly scheduled annual meeting of stockholders that occurs following the Grant Date, subject to the Reporting Person's continued service to the Issuer through such vesting date or, if earlier, such annual meeting. Each RSU represents the contingent right to receive one share of the Issuer's Common Stock. F1 · derivative.exercise_date: Represents restricted stock units ("RSUs") that vest 12 months from June 15, 2020 ("Grant Date"), provided that these RSUs vest in full on the Issuer's next regularly scheduled annual meeting of stockholders that occurs following the Grant Date, subject to the Reporting Person's continued service to the Issuer through such vesting date or, if earlier, such annual meeting. Each RSU represents the contingent right to receive one share of the Issuer's Common Stock. F1 · derivative.expiration_date: Represents restricted stock units ("RSUs") that vest 12 months from June 15, 2020 ("Grant Date"), provided that these RSUs vest in full on the Issuer's next regularly scheduled annual meeting of stockholders that occurs following the Grant Date, subject to the Reporting Person's continued service to the Issuer through such vesting date or, if earlier, such annual meeting. Each RSU represents the contingent right to receive one share of the Issuer's Common Stock. Read SEC document |
| June 08, 2020 Filed Jun 9, 2020 20:17 UTC | Akebia Therapeutics, Inc. AKBA · Entity 6105 | SaleCommon Stock | 4,567 | $12.10 | $55,260.70 |
DisclosureSEC source: 0001562180-20-004360 · primarydocument.xml · nonDerivative · entry 2 Smith Cynthia · CIK 0001609480 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,833 F2 · kind: This sale was made pursuant to a 10b5-1 trading plan to cover tax withholding obligations in connection with the vesting and settlement of 100% of the Reporting Person's restricted stock units granted on June 6, 2019. Read SEC document |
| June 05, 2020 Filed Jun 9, 2020 20:17 UTC | Akebia Therapeutics, Inc. AKBA · Entity 6105 | GrantStock Option (Right to buy) · Derivative | 20,100 | $0.00 Strike: $11.96 | $0.00 |
DisclosureSEC source: 0001562180-20-004360 · primarydocument.xml · derivative · entry 3 Smith Cynthia · CIK 0001609480 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,100 Underlying: Common Stock · 20,100 shares Expires 2030-06-05 F3 · shares: Represents an option to purchase shares of the Issuer's common stock granted by the Issuer pursuant to its 2014 Incentive Plan, as amended, as provided by the Issuer's Amended and Restated Non-Employee Director Compensation Program (the "Stock Option"). 100% of the Stock Option will vest and become exercisable on the first anniversary of the grant date, subject to the Reporting Person's continued service to the Issuer. Read SEC document |
| June 05, 2020 Filed Jun 9, 2020 20:17 UTC | Akebia Therapeutics, Inc. AKBA · Entity 6105 | GrantCommon Stock | 13,700 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-20-004360 · primarydocument.xml · nonDerivative · entry 1 Smith Cynthia · CIK 0001609480 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,400 F1 · shares: The restricted stock units were granted by the Issuer pursuant to its 2014 Incentive Plan, as amended, as provided by the Issuer's Amended and Restated Non-Employee Director Compensation Program (the "RSUs"). 100% of the RSUs will vest on the first anniversary of the grant date, subject to the Reporting Person's continued service to the Issuer. Read SEC document |
| November 20, 2019 Filed Nov 22, 2019 11:20 UTC | Akebia Therapeutics, Inc. AKBA · Entity 6105 | PurchaseCommon Stock | 15,000 | $3.52 | $52,800.00 |
DisclosureSEC source: 0001562180-19-005641 · primarydocument.xml · nonDerivative · entry 1 Smith Cynthia · CIK 0001609480 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,700 F1 · kind: The purchase reported in this Form 4 was made on the open market. Read SEC document |
| June 20, 2019 Filed Jun 21, 2019 20:00 UTC | Dicerna Pharmaceuticals Inc DRNA · Entity 131951 | GrantDirector Stock Option (right to buy) · Derivative | 25,000 | $0.00 Strike: $15.44 | $0.00 |
DisclosureSEC source: 0000899243-19-017858 · doc4.xml · derivative · entry 1 Smith Cynthia · CIK 0001609480 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2029-06-20 F1 · derivative.exercise_date: This option vests monthly over 12 months from June 20, 2019 ("Grant Date") in substantially equal monthly installments, provided that the option will vest in full on the Issuer's next regularly scheduled annual meeting of stockholders that occurs following the Grant Date, subject to the Reporting Person's continued service to the Issuer through each such date or, if earlier, such annual meeting. Read SEC document |
| June 06, 2019 Filed Jun 10, 2019 20:04 UTC | Akebia Therapeutics, Inc. AKBA · Entity 6105 | GrantStock Option (Right to buy) · Derivative | 20,100 | $0.00 Strike: $4.23 | $0.00 |
DisclosureSEC source: 0001562180-19-003440 · primarydocument.xml · derivative · entry 2 Smith Cynthia · CIK 0001609480 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,100 Underlying: Common Stock · 20,100 shares Expires 2029-06-06 F2 · shares: Represents an option to purchase shares of the Issuer's common stock granted by the Issuer pursuant to its 2014 Incentive Plan, as amended, as provided by the Issuer's Amended and Restated Non-Employee Director Compensation Program (the "Stock Option"). 100% of the Stock Option will vest and become exercisable on the first anniversary of the grant date, subject to the Reporting Person's continued service to the Issuer. Read SEC document |
| June 06, 2019 Filed Jun 10, 2019 20:04 UTC | Akebia Therapeutics, Inc. AKBA · Entity 6105 | GrantCommon Stock | 13,700 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-19-003440 · primarydocument.xml · nonDerivative · entry 1 Smith Cynthia · CIK 0001609480 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,700 F1 · shares: The restricted stock units were granted by the Issuer pursuant to its 2014 Incentive Plan, as amended, as provided by the Issuer's Amended and Restated Non-Employee Director Compensation Program (the "RSUs"). 100% of the RSUs will vest on the first anniversary of the grant date, subject to the Reporting Person's continued service to the Issuer. Read SEC document |
| June 05, 2019 Filed Jun 5, 2019 22:54 UTC | Spero Therapeutics, Inc. SPRO · Entity 7014 | GrantStock Option (right to buy) · Derivative | 6,073 | $0.00 Strike: $10.67 | $0.00 |
DisclosureSEC source: 0000899243-19-015673 · doc4.xml · derivative · entry 1 Smith Cynthia · CIK 0001609480 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,073 Underlying: Common Stock · 6,073 shares Expires 2029-06-05 F1 · derivative.exercise_date: The shares underlying this option will vest and become exercisable in full on June 5, 2020 subject to the Reporting Person's continued service as a director through the vesting date. Read SEC document |
| March 29, 2019 Filed Mar 29, 2019 23:29 UTC | Spero Therapeutics, Inc. SPRO · Entity 7014 | GrantStock Option (right to buy) · Derivative | 12,146 | $0.00 Strike: $12.81 | $0.00 |
DisclosureSEC source: 0000899243-19-009318 · doc4.xml · derivative · entry 1 Smith Cynthia · CIK 0001609480 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,146 Underlying: Common Stock · 12,146 shares Expires 2029-03-29 F1 · derivative.exercise_date: The shares underlying this option will vest in thirty-six equal monthly installments at the end of each successive month following March 29, 2019, subject to the Reporting Person's continued service as a director through the applicable vesting dates. Read SEC document |
| August 28, 2018 Filed Aug 29, 2018 20:02 UTC | Akebia Therapeutics, Inc. AKBA · Entity 6105 | GrantStock Option (Right to buy) · Derivative | 25,000 | $0.00 Strike: $8.25 | $0.00 |
DisclosureSEC source: 0001562180-18-003795 · primarydocument.xml · derivative · entry 1 Smith Cynthia · CIK 0001609480 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2028-08-28 F1 · derivative.exercise_date: 25% of this option will vest on the first anniversary of the grant date with the remaining 75% vesting in equal quarterly installments thereafter. Read SEC document |
| August 13, 2018 Filed Aug 15, 2018 21:01 UTC | Dicerna Pharmaceuticals Inc DRNA · Entity 131951 | GrantDirector Stock Option (Right to Buy) · Derivative | 25,000 | $0.00 Strike: $14.76 | $0.00 |
DisclosureSEC source: 0000905148-18-000716 · form4.xml · derivative · entry 1 Smith Cynthia · CIK 0001609480 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2028-08-13 F1 · derivative.exercise_date: This option vests as to one-third of the underlying shares on the one year anniversary of the date of grant and as to the remaining two-thirds of the shares in quarterly installments over the two-year period thereafter, subject in each case to the Reporting Person's continued service through the applicable vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.